HBOT for Stroke Recovery: 2026 Neuroplasticity & Clinical Outcomes Data

Stroke: The Scale of the Problem

Stroke survivors treated with HBOT showed a 15-point improvement on the National Institutes of Health Stroke Scale in one controlled trial, with SPECT imaging confirming reactivation of dormant brain tissue. Approximately 795,000 Americans have a stroke each year, and over 7 million survivors live with lasting impairment. Standard rehabilitation helps, but many patients plateau. HBOT targets the stunned but viable tissue that conventional therapy cannot reach.

The concept that HBOT could reactivate dormant brain tissue and extend the recovery window has been studied primarily by Professor Shai Efrati’s group at the Sagol Center in Israel, with results that challenge conventional wisdom about stroke recovery timelines.

What Does the Research Say?

The statistics tell two different stories depending on when HBOT is applied.

Chronic Stroke: The Strongest Data

Hadanny et al. (2020): The Largest Cognitive Outcomes Study

This retrospective analysis of 162 chronic stroke patients (75.3% male, mean age 60.75 years, 74.6% ischemic, 53.7% left hemisphere) provides the largest dataset on HBOT in stroke recovery:¹

• 86% achieved clinically significant improvement (more than 0.5 SD in cognitive scores)
• All cognitive domains improved significantly (P < 0.05)
• No significant difference between cortical and subcortical strokes
• Hemorrhagic strokes showed significantly higher improvement in information processing speed
• Left hemisphere strokes had higher motor domain improvement
• Baseline cognitive function was a significant predictor of improvement in all domains
• Gains documented in patients 3–190 months post-stroke

Efrati et al. (2013): The Landmark Crossover RCT

This prospective, randomized, controlled crossover trial of 74 chronic stroke patients (6–36 months post-stroke) remains the most methodologically rigorous study to date:²

The crossover design strengthened the findings: the control group showed no improvement during the waiting period, then showed similar improvements when they received HBOT. This directly rules out spontaneous recovery as an explanation.

Khairy et al. (2025): Imaging Correlation

A single-subject case with 83 sessions over 16 weeks documented:⁵

• Right motor cortex perfusion: +15.83%
• Right frontal lobe perfusion: +15.92%
• DTI: increased fractional anisotropy in major white matter tracts
• Functional: progression from wheelchair to ambulation with cane

Acute Stroke: What the Evidence Actually Says

For acute ischemic stroke (within hours of onset), the data is not supportive of HBOT:

• Cochrane Review (Bennett et al. 2014): 11 RCTs, 705 participants. No mortality benefit (RR 0.97, P = 0.96). Only 4 of 14 disability scales showed improvement.³
• BMC Neurology meta-analysis (Li et al. 2024): 8 RCTs, 493 patients. No significant differences in NIHSS (MD -1.41, P = NS) or Barthel index (MD 8.85, P = NS).⁴

Standard acute stroke protocols (thrombolysis, mechanical thrombectomy) remain the only evidence-based treatments for acute stroke. HBOT is not indicated in the acute phase.

The Neuroplasticity Mechanism

HBOT’s effect on chronic stroke recovery is theorized to work through reactivation of the ischemic penumbra: the zone of stunned but not dead brain tissue surrounding the stroke core. Under normal oxygen conditions, this tissue remains metabolically dormant. Under HBOT conditions, dramatically elevated oxygen delivery can:

1. Reactivate stunned neurons in the penumbra region that have been metabolically silent
2. Stimulate angiogenesis in areas with compromised blood supply
3. Promote neurogenesis and synaptogenesis, building new neural connections
4. Reduce chronic neuroinflammation in injured brain tissue

SPECT imaging before and after treatment consistently shows increased cerebral blood flow and metabolic activity in peri-infarct regions, providing objective evidence that HBOT produces measurable biological changes in the brain. This aligns with before and after results seen across neurological HBOT applications.

What Does the HBOT Protocol Look Like?

The protocol used in evidence-based chronic stroke trials:

• Pressure: 2.0 ATA in a hard chamber
• Oxygen: 100% medical-grade oxygen
• Session duration: 90 minutes at treatment pressure
• Frequency: 5 sessions per week
• Course length: 40–60 sessions (8–12 weeks)

The 40–60 session course is longer than most HBOT protocols for other conditions, reflecting the complexity of neuroplastic repair and the need for sustained metabolic stimulation to reactivate dormant neural tissue. Soft chambers are not appropriate for this indication.

Limitations and Honest Assessment

• Limited research groups: Most positive chronic stroke data comes from a single group (Efrati/Sagol Center, Israel). Independent replication with sham controls is needed.
• Sample sizes: The largest published RCT included 74 patients. The 162-patient study was retrospective, not randomized.
• Patient selection: Patients with large completed infarcts and minimal surviving penumbral tissue are unlikely to benefit.
• Cost barrier: At $200–$400 per session, a 60-session course costs $12,000–$24,000 out of pocket.
• No insurance coverage: Stroke recovery is not among the 14 FDA-cleared indications.

Sources

1. Hadanny A et al. HBOT improves neurocognitive functions of post-stroke patients. Restor Neurol Neurosci. 2020;38(1):93-108.
2. Efrati S et al. Hyperbaric Oxygen Induces Late Neuroplasticity in Post Stroke Patients. PLoS ONE. 2013;8(1):e53716. DOI: 10.1371/journal.pone.0053716
3. Bennett MH et al. Hyperbaric oxygen therapy for acute ischaemic stroke. Cochrane Database Syst Rev. 2014;(11):CD004954. DOI: 10.1002/14651858.CD004954.pub3
4. Li X et al. Efficacy and safety of HBOT in acute ischaemic stroke. BMC Neurol. 2024;24:51. DOI: 10.1186/s12883-024-03555-w
5. Khairy S et al. Brain imaging correlation of neurological improvements following HBOT. J Med Case Rep. 2025;19:87. DOI: 10.1186/s13256-025-05577-5
6. Yadav R et al. Role of HBOT in Rehabilitation of Stroke Patients. Ann Afr Med. 2026. DOI: 10.4103/aam.aam_804_25
7. Rosario ER et al. Effect of HBOT on Functional Impairments Caused by Ischemic Stroke. Neurol Res Int. 2018;2018:3172679. DOI: 10.1155/2018/3172679
8. Iqbal J et al. Hyperbaric Oxygen and Outcomes Following Brain Injury. J Neurol Res Rev Rep. 2023;5:178. DOI: 10.47363/jnrrr/2023(5)178
9. Carson S et al. HBOT for stroke: a systematic review. Clin Rehabil. 2005;19(8):819-833. DOI: 10.1191/0269215505cr907oa

Seph Fontane Pennock

Author

Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.

Website